A first reported case of metastatic anorectal amelanotic melanoma with a marked response to anti-PD-1 antibody nivolumab: A case report
| Autor: | Katsuji Tokuhara, Masanori Kon, Hirotsugu Tanimura, Takahiro Kiyohara, Kazuhiko Yoshioka, Kazuyoshi Nakatani |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Amelanotic melanoma
Poor prognosis medicine.medical_specialty Pathology Anorectal melanoma business.industry Anti-PD-1 antibody Standard treatment Anti pd 1 Case Report medicine.disease Dermatology 03 medical and health sciences Nivolumab 0302 clinical medicine 030220 oncology & carcinogenesis medicine 030211 gastroenterology & hepatology Surgery business Rare disease |
| Zdroj: | International Journal of Surgery Case Reports |
| ISSN: | 2210-2612 |
| DOI: | 10.1016/j.ijscr.2017.01.028 |
| Popis: | Highlights • We report a first case of nivolumab reduction of metastatic anorectal amelanotic melanoma (AAMM). • Multimodal therapy including nivolumab will be effective also for non-cutaneous AAMM. Introduction Anorectal amelanotic melanoma (AAMM) is a rare disease with poor prognosis. A standard treatment strategy for AAMM has not been established. Presentation of case We report a case of successful treatment of AAMM with nivolumab. A 67-year-old man was referred for colonoscopy which revealed type I tumor in the rectum. AAMM was diagnosed with immunostaining histopathological biopsy findings. Enhanced computed tomography (ECT) revealed the rectal tumor without distant organ metastasis. We performed laparoscopy-assisted abdominoperineal resection. ECT at three months after surgery revealed liver metastases and right ischial bone metastasis. Although we had started dacarbazine monotherapy, black spots that were suspicious of skin metastases had appeared on systemic skin. Therefore, we started nivolumab therapy. ECT at 3 months after initiation of nivolumab showed shrinkage of liver metastasis. We have continued strict follow-up every 2 months and checked no oncologic progression at 17 months after initiation of nivolumab. Discussion The anti-PD-1 antibody have improved prognosis of malignant melanoma. However, there are no reports of nivolumab for treatment of AAMM. Conclusions Our patient is the first reported case of AAMM treated with nivolumab. We consider that nivolumab will be effective for non-cutaneous malignant melanoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|